What is the EV/FCF ratio for MeiraGTx Holdings plc (MGTX)?

The EV/FCF ratio for MGTX stock is N/A.

What is the estimated TTM average EV/FCF ratio for MeiraGTx Holdings plc (MGTX)?

The estimated TTM average EV/FCF ratio for MGTX stock is 19.90x.

Compare

MeiraGTx Holdings plc(MGTX)

Biotechnology · New York City, NY

$10.78-0.14 (-1.33%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

Compare

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:27:46.255Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:27:46.255Z.

Quote observation: 2026-10-06T15:25:36.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 997,867,327
Total debt · period ending 2026-06-30: 112,321,000
Cash · period ending 2026-06-30: 143,166,000
TTM free cash flow · period ending 2026-06-30: N/A

FMP input reference: f5440d38f147f42472ad3502ccef0af83b0bc0ea844c0df361be04396bb1fdd1

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

EV/FCF Ratio

MGTX EV/FCF Ratio Chart

N/A

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2020-05-07.

MGTX EV/FCF Ratio

MGTX Average EV/FCF Ratio Chart

MGTX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

EV/FCF RATIO AVG TTM

19.90x

EV/FCF RATIO AVG 3Y

N/A

EV/FCF RATIO AVG 5Y

N/A

EV/FCF RATIO AVG 10Y

N/A

EV/FCF RATIO AVG 15Y

N/A

EV/FCF RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MGTX Competitors' EV/FCF Ratio

MGTX

MeiraGTx Holdings plc

Current

Market Cap

$997.87M

EV/FCF Ratio

N/A

TTM Avg

19.90x

3Y Avg

N/A

5Y Avg

N/A

AKTS

Aktis Oncology, Inc.

vs MGTX

Market Cap

$997.87M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRCT

PROCEPT BioRobotics Corporation

vs MGTX

Market Cap

$997.50M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTGO

Latigo Biotherapeutics Inc.

vs MGTX

Market Cap

$1.01B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PCRX

Pacira BioSciences, Inc.

vs MGTX

Market Cap

$987.89M

EV/FCF Ratio

6.65x

TTM Avg

9.54x

3Y Avg

10.29x

5Y Avg

18.38x

LBRX

LB Pharmaceuticals Inc Common Stock

vs MGTX

Market Cap

$1.01B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LMRI

Lumexa Imaging Holdings, Inc. Common Stock

vs MGTX

Market Cap

$1.02B

EV/FCF Ratio

60.58x

TTM Avg

62.48x

3Y Avg

62.48x

5Y Avg

62.48x

IART

Integra LifeSciences Holdings Corporation

vs MGTX

Market Cap

$1.02B

EV/FCF Ratio

N/A

TTM Avg

99.90x

3Y Avg

55.01x

5Y Avg

50.88x

IMTX

Immatics N.V.

vs MGTX

Market Cap

$1.03B

EV/FCF Ratio

N/A

TTM Avg

4.12x

3Y Avg

4.43x

5Y Avg

22.97x

CSTL

Castle Biosciences, Inc.

vs MGTX

Market Cap

$1.04B

EV/FCF Ratio

N/A

TTM Avg

53.87x

3Y Avg

38.43x

5Y Avg

50.64x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
MeiraGTx Holdings plc (MGTX)	$997.87M	N/A	19.90x	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$997.87M	N/A	N/A	N/A	N/A
PROCEPT BioRobotics Corporation (PRCT)vs ›	$997.50M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$1.01B	N/A	N/A	N/A	N/A
Pacira BioSciences, Inc. (PCRX)vs ›	$987.89M	6.65x	9.54x	10.29x	18.38x
LB Pharmaceuticals Inc Common Stock (LBRX)vs ›	$1.01B	N/A	N/A	N/A	N/A
Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs ›	$1.02B	60.58x	62.48x	62.48x	62.48x
Integra LifeSciences Holdings Corporation (IART)vs ›	$1.02B	N/A	99.90x	55.01x	50.88x
Immatics N.V. (IMTX)vs ›	$1.03B	N/A	4.12x	4.43x	22.97x
Castle Biosciences, Inc. (CSTL)vs ›	$1.04B	N/A	53.87x	38.43x	50.64x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio FAQ

What is the EV/FCF ratio for MeiraGTx Holdings plc (MGTX)?: The EV/FCF ratio for MGTX stock is N/A.
What is the estimated TTM average EV/FCF ratio for MeiraGTx Holdings plc (MGTX)?: The estimated TTM average EV/FCF ratio for MGTX stock is 19.90x.

MGTX EV/FCF Ratio History

DATE	EV/FCF RATIO
2020-05-07	28.26x
2020-05-06	25.55x
2020-05-05	27.34x
2020-05-04	28.00x
2020-05-01	24.23x
2020-04-30	27.14x
2020-04-29	29.55x
2020-04-28	27.54x
2020-04-27	29.03x
2020-04-24	27.57x
2020-04-23	26.38x
2020-04-22	26.54x
2020-04-21	26.74x
2020-04-20	26.54x
2020-04-17	29.85x
2020-04-16	25.48x
2020-04-15	26.24x
2020-04-14	27.83x
2020-04-13	26.97x
2020-04-09	26.34x
2020-04-08	25.42x
2020-04-07	22.67x
2020-04-06	26.21x
2020-04-03	20.72x
2020-04-02	20.58x
2020-04-01	22.60x
2020-03-31	26.05x
2020-03-30	22.80x
2020-03-27	20.15x
2020-03-26	25.12x
2020-03-25	21.48x
2020-03-24	17.54x
2020-03-23	14.39x
2020-03-20	12.84x
2020-03-19	16.21x
2020-03-18	12.81x
2020-03-17	13.53x
2020-03-16	12.38x
2020-03-13	24.36x
2020-03-12	21.68x
2020-03-11	14.80x
2020-03-10	17.03x
2020-03-09	17.01x
2020-03-06	19.48x
2020-03-05	21.74x
2020-03-04	23.28x
2020-03-03	19.40x
2020-03-02	20.39x
2020-02-28	18.98x
2020-02-27	18.13x
2020-02-26	19.54x
2020-02-25	19.90x
2020-02-24	20.89x
2020-02-21	23.20x
2020-02-20	22.18x
2020-02-19	21.57x
2020-02-18	22.68x
2020-02-14	24.31x
2020-02-13	27.51x
2020-02-12	29.00x
2020-02-11	28.13x
2020-02-10	27.29x
2020-02-07	26.10x
2020-02-06	26.10x
2020-02-05	25.20x
2020-02-04	25.22x
2020-02-03	25.30x
2020-01-31	22.78x
2020-01-30	23.20x
2020-01-29	22.58x
2020-01-28	21.37x
2020-01-27	21.98x
2020-01-24	22.94x
2020-01-23	24.63x
2020-01-22	25.15x
2020-01-21	25.05x
2020-01-17	27.29x
2020-01-16	27.77x
2020-01-15	26.78x
2020-01-14	26.74x
2020-01-13	26.48x
2020-01-10	25.36x
2020-01-09	27.81x
2020-01-08	27.13x
2020-01-07	27.07x
2020-01-06	26.58x
2020-01-03	25.76x
2020-01-02	25.98x
2019-12-31	26.58x
2019-12-30	26.34x
2019-12-27	26.78x
2019-12-26	28.80x
2019-12-24	29.48x
2019-12-23	29.46x
2019-12-20	28.76x
2019-12-19	29.38x
2019-12-18	29.26x
2019-12-17	29.28x
2019-12-16	28.65x
2019-12-13	28.57x
2019-12-12	27.57x
2019-12-11	27.65x
2019-12-10	29.04x
2019-12-09	29.14x
2019-12-06	29.00x
2019-12-05	26.46x
2019-12-04	26.59x
2019-12-03	27.57x
2019-12-02	24.09x
2019-11-29	25.09x
2019-11-27	25.07x
2019-11-26	21.94x
2019-11-25	21.51x
2019-11-22	22.18x
2019-11-21	20.71x
2019-11-20	18.52x
2019-11-19	18.50x
2019-11-18	16.30x
2019-11-15	16.81x
2019-11-14	16.04x
2019-11-13	16.93x
2019-11-12	16.93x
2019-11-11	17.47x
2019-11-08	15.52x
2019-11-07	11.12x
2019-11-06	10.83x
2019-11-05	11.35x
2019-11-04	11.62x
2019-11-01	13.12x
2019-10-31	11.12x
2019-10-30	10.95x
2019-10-29	11.07x
2019-10-28	11.03x
2019-10-25	11.58x
2019-10-24	11.30x
2019-10-23	11.05x
2019-10-22	10.97x
2019-10-21	11.33x
2019-10-18	10.70x
2019-10-17	11.82x
2019-10-16	11.37x
2019-10-15	10.44x
2019-10-14	10.79x
2019-10-11	11.02x
2019-10-10	11.16x
2019-10-09	11.34x
2019-10-08	11.54x
2019-10-07	12.73x
2019-10-04	13.34x
2019-10-03	13.74x
2019-10-02	12.88x
2019-10-01	12.38x
2019-09-30	13.03x
2019-09-27	12.89x
2019-09-26	13.20x
2019-09-25	13.95x
2019-09-24	15.03x
2019-09-23	16.05x
2019-09-20	16.01x
2019-09-19	16.59x
2019-09-18	16.75x
2019-09-17	16.35x
2019-09-16	17.13x
2019-09-13	17.65x
2019-09-12	17.72x
2019-09-11	18.77x
2019-09-10	17.60x
2019-09-09	17.41x
2019-09-06	17.74x
2019-09-05	18.46x
2019-09-04	18.16x
2019-09-03	19.33x
2019-08-30	18.50x
2019-08-29	18.96x
2019-08-28	18.33x
2019-08-27	17.93x
2019-08-26	19.43x
2019-08-23	20.14x
2019-08-22	20.78x
2019-08-21	20.61x
2019-08-20	19.85x
2019-08-19	19.77x
2019-08-16	19.59x
2019-08-15	19.66x
2019-08-14	21.07x
2019-08-13	21.29x
2019-08-12	20.23x
2019-08-09	20.93x
2019-08-08	21.71x
2019-08-07	17.36x
2019-08-06	17.27x
2019-08-05	16.65x
2019-08-02	17.98x
2019-08-01	18.37x
2019-07-31	18.99x
2019-07-30	19.64x
2019-07-29	20.48x
2019-07-26	19.71x
2019-07-25	19.50x
2019-07-24	20.66x
2019-07-23	18.75x
2019-07-22	18.77x
2019-07-19	18.78x
2019-07-18	19.51x
2019-07-17	20.58x
2019-07-16	20.04x
2019-07-15	20.40x
2019-07-12	20.91x
2019-07-11	21.09x
2019-07-10	21.13x
2019-07-09	21.68x
2019-07-08	20.62x
2019-07-05	18.70x
2019-07-03	21.32x
2019-07-02	20.77x
2019-07-01	19.79x
2019-06-28	18.63x
2019-06-27	17.13x
2019-06-26	15.68x
2019-06-25	14.83x
2019-06-24	13.36x
2019-06-21	13.17x
2019-06-20	12.80x
2019-06-19	13.17x
2019-06-18	13.19x
2019-06-17	12.63x
2019-06-14	12.42x
2019-06-13	13.83x
2019-06-12	13.28x
2019-06-11	12.71x
2019-06-10	12.83x
2019-06-07	12.89x
2019-06-06	12.52x
2019-06-05	13.68x
2019-06-04	14.17x
2019-06-03	13.43x
2019-05-31	13.88x
2019-05-30	13.75x
2019-05-29	14.80x
2019-05-28	16.37x
2019-05-24	16.16x
2019-05-23	15.76x
2019-05-22	15.81x
2019-05-21	15.80x
2019-05-20	15.27x
2019-05-17	15.32x
2019-05-16	14.92x
2019-05-15	14.09x

About MeiraGTx Holdings plc

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

New York City, NY

393 employees

www.meiragtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alexandria Forbes

View full financials

NAME

MARKET CAP

EV/FCF RATIO

TTM

MeiraGTx Holdings plc (MGTX)

$997.87M

N/A

19.90x

N/A

Aktis Oncology, Inc. (AKTS)vs ›

$997.87M

N/A

PROCEPT BioRobotics Corporation (PRCT)vs ›

$997.50M

N/A

Latigo Biotherapeutics Inc. (LTGO)vs ›

$1.01B

N/A

Pacira BioSciences, Inc. (PCRX)vs ›

$987.89M

6.65x

9.54x

10.29x

18.38x

LB Pharmaceuticals Inc Common Stock (LBRX)vs ›

$1.01B

N/A

Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs ›

$1.02B

60.58x

62.48x

Integra LifeSciences Holdings Corporation (IART)vs ›

$1.02B

N/A

99.90x

55.01x

50.88x

Immatics N.V. (IMTX)vs ›

$1.03B

N/A

4.12x

4.43x

22.97x

Castle Biosciences, Inc. (CSTL)vs ›

$1.04B

N/A

53.87x

38.43x

50.64x

DATE

EV/FCF RATIO

2020-05-07

28.26x

2020-05-06

25.55x

2020-05-05

27.34x

2020-05-04

28.00x

2020-05-01

24.23x

2020-04-30

27.14x

2020-04-29

29.55x

2020-04-28

27.54x

2020-04-27

29.03x

2020-04-24

27.57x

2020-04-23

26.38x

2020-04-22

26.54x

2020-04-21

26.74x

2020-04-20

26.54x

2020-04-17

29.85x

2020-04-16

25.48x

2020-04-15

26.24x

2020-04-14

27.83x

2020-04-13

26.97x

2020-04-09

26.34x

2020-04-08

25.42x

2020-04-07

22.67x

2020-04-06

26.21x

2020-04-03

20.72x

2020-04-02

20.58x

2020-04-01

22.60x

2020-03-31

26.05x

2020-03-30

22.80x

2020-03-27

20.15x

2020-03-26

25.12x

2020-03-25

21.48x

2020-03-24

17.54x

2020-03-23

14.39x

2020-03-20

12.84x

2020-03-19

16.21x

2020-03-18

12.81x

2020-03-17

13.53x

2020-03-16

12.38x

2020-03-13

24.36x

2020-03-12

21.68x

2020-03-11

14.80x

2020-03-10

17.03x

2020-03-09

17.01x

2020-03-06

19.48x

2020-03-05

21.74x

2020-03-04

23.28x

2020-03-03

19.40x

2020-03-02

20.39x

2020-02-28

18.98x

2020-02-27

18.13x

2020-02-26

19.54x

2020-02-25

19.90x

2020-02-24

20.89x

2020-02-21

23.20x

2020-02-20

22.18x

2020-02-19

21.57x

2020-02-18

22.68x

2020-02-14

24.31x

2020-02-13

27.51x

2020-02-12

29.00x

2020-02-11

28.13x

2020-02-10

27.29x

2020-02-07

26.10x

2020-02-06

26.10x

2020-02-05

25.20x

2020-02-04

25.22x

2020-02-03

25.30x

2020-01-31

22.78x

2020-01-30

23.20x

2020-01-29

22.58x

2020-01-28

21.37x

2020-01-27

21.98x

2020-01-24

22.94x

2020-01-23

24.63x

2020-01-22

25.15x

2020-01-21

25.05x

2020-01-17

27.29x

2020-01-16

27.77x

2020-01-15

26.78x

2020-01-14

26.74x

2020-01-13

26.48x

2020-01-10

25.36x

2020-01-09

27.81x

2020-01-08

27.13x

2020-01-07

27.07x

2020-01-06

26.58x

2020-01-03

25.76x

2020-01-02

25.98x

2019-12-31

26.58x

2019-12-30

26.34x

2019-12-27

26.78x

2019-12-26

28.80x

2019-12-24

29.48x

2019-12-23

29.46x

2019-12-20

28.76x

2019-12-19

29.38x

2019-12-18

29.26x

2019-12-17

29.28x

2019-12-16

28.65x

2019-12-13

28.57x

2019-12-12

27.57x

2019-12-11

27.65x

2019-12-10

29.04x

2019-12-09

29.14x

2019-12-06

29.00x

2019-12-05

26.46x

2019-12-04

26.59x

2019-12-03

27.57x

2019-12-02

24.09x

2019-11-29

25.09x

2019-11-27

25.07x

2019-11-26

21.94x

2019-11-25

21.51x

2019-11-22

22.18x

2019-11-21

20.71x

2019-11-20

18.52x

2019-11-19

18.50x

2019-11-18

16.30x

2019-11-15

16.81x

2019-11-14

16.04x

2019-11-13

16.93x

2019-11-12

16.93x

2019-11-11

17.47x

2019-11-08

15.52x

2019-11-07

11.12x

2019-11-06

10.83x

2019-11-05

11.35x

2019-11-04

11.62x

2019-11-01

13.12x

2019-10-31

11.12x

2019-10-30

10.95x

2019-10-29

11.07x

2019-10-28

11.03x

2019-10-25

11.58x

2019-10-24

11.30x

2019-10-23

11.05x

2019-10-22

10.97x

2019-10-21

11.33x

2019-10-18

10.70x

2019-10-17

11.82x

2019-10-16

11.37x

2019-10-15

10.44x

2019-10-14

10.79x

2019-10-11

11.02x

2019-10-10

11.16x

2019-10-09

11.34x

2019-10-08

11.54x

2019-10-07

12.73x

2019-10-04

13.34x

2019-10-03

13.74x

2019-10-02

12.88x

2019-10-01

12.38x

2019-09-30

13.03x

2019-09-27

12.89x

2019-09-26

13.20x

2019-09-25

13.95x

2019-09-24

15.03x

2019-09-23

16.05x

2019-09-20

16.01x

2019-09-19

16.59x

2019-09-18

16.75x

2019-09-17

16.35x

2019-09-16

17.13x

2019-09-13

17.65x

2019-09-12

17.72x

2019-09-11

18.77x

2019-09-10

17.60x

2019-09-09

17.41x

2019-09-06

17.74x

2019-09-05

18.46x

2019-09-04

18.16x

2019-09-03

19.33x

2019-08-30

18.50x

2019-08-29

18.96x

2019-08-28

18.33x

2019-08-27

17.93x

2019-08-26

19.43x

2019-08-23

20.14x

2019-08-22

20.78x

2019-08-21

20.61x

2019-08-20

19.85x

2019-08-19

19.77x

2019-08-16

19.59x

2019-08-15

19.66x

2019-08-14

21.07x

2019-08-13

21.29x

2019-08-12

20.23x

2019-08-09

20.93x

2019-08-08

21.71x

2019-08-07

17.36x

2019-08-06

17.27x

2019-08-05

16.65x

2019-08-02

17.98x

2019-08-01

18.37x

2019-07-31

18.99x

2019-07-30

19.64x

2019-07-29

20.48x

2019-07-26

19.71x

2019-07-25

19.50x

2019-07-24

20.66x

2019-07-23

18.75x

2019-07-22

18.77x

2019-07-19

18.78x

2019-07-18

19.51x

2019-07-17

20.58x

2019-07-16

20.04x

2019-07-15

20.40x

2019-07-12

20.91x

2019-07-11

21.09x

2019-07-10

21.13x

2019-07-09

21.68x

2019-07-08

20.62x

2019-07-05

18.70x

2019-07-03

21.32x

2019-07-02

20.77x

2019-07-01

19.79x

2019-06-28

18.63x

2019-06-27

17.13x

2019-06-26

15.68x

2019-06-25

14.83x

2019-06-24

13.36x

2019-06-21

13.17x

2019-06-20

12.80x

2019-06-19

13.17x

2019-06-18

13.19x

2019-06-17

12.63x

2019-06-14

12.42x

2019-06-13

13.83x

2019-06-12

13.28x

2019-06-11

12.71x

2019-06-10

12.83x

2019-06-07

12.89x

2019-06-06

12.52x

2019-06-05

13.68x

2019-06-04

14.17x

2019-06-03

13.43x

2019-05-31

13.88x

2019-05-30

13.75x

2019-05-29

14.80x

2019-05-28

16.37x

2019-05-24

16.16x

2019-05-23

15.76x

2019-05-22

15.81x

2019-05-21

15.80x

2019-05-20

15.27x

2019-05-17

15.32x

2019-05-16

14.92x

2019-05-15

14.09x

EV/FCF Ratio: N/A

MGTX EV/FCF Ratio Chart

MGTX Average EV/FCF Ratio Chart

MGTX EV/FCF Ratio Metrics

MGTX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

EV/FCF Ratio FAQ

MGTX EV/FCF Ratio History

Related Metrics

EV/FCF Ratio: N/A

MGTX EV/FCF Ratio Chart

MGTX Average EV/FCF Ratio Chart

MGTX EV/FCF Ratio Metrics

MGTX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

EV/FCF Ratio FAQ

MGTX EV/FCF Ratio History

Related Metrics